-
公开(公告)号：US09061037B2
公开(公告)日：2015-06-23
申请号：US13051102
申请日：2011-03-18
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC分类号： A61K31/69 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/4965 , A61K47/10
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
公开(公告)号：US20120172808A1
公开(公告)日：2012-07-05
申请号：US13431313
申请日：2012-03-27
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
公开(公告)号：US09180093B2
公开(公告)日：2015-11-10
申请号：US13592235
申请日：2012-08-22
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
公开(公告)号：US20110230441A1
公开(公告)日：2011-09-22
申请号：US13051102
申请日：2011-03-18
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC分类号： A61K31/69 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/4965 , A61K47/10
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
摘要翻译： 硼替佐米的多剂量制剂被提出，其中硼替佐米具有显着改善的稳定性。 特别优选的制剂包括硼替佐米是适合注射的液体形式的制剂，其中溶剂体系主要包含丙二醇。 在其他优选方面，硼替佐米作为具有异双功能路易斯碱的路易斯供体 - 受体复合物存在。
-
公开(公告)号：US20120322762A1
公开(公告)日：2012-12-20
申请号：US13592228
申请日：2012-08-22
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
IPC分类号： A61K31/69
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
摘要翻译： 硼替佐米的多剂量制剂被提出，其中硼替佐米具有显着改善的稳定性。 特别优选的制剂包括硼替佐米是适合注射的液体形式的制剂，其中溶剂体系主要包含丙二醇。 在其他优选方面，硼替佐米作为具有异双功能路易斯碱的路易斯供体 - 受体复合物存在。
-
公开(公告)号：US08263578B2
公开(公告)日：2012-09-11
申请号：US13431313
申请日：2012-03-27
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
IPC分类号： A01N55/08 , A61K31/69 , A61K31/4965 , C07F5/02 , C07F5/04 , C07F7/02 , C07D241/00 , C07D241/02
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
摘要翻译： 硼替佐米的多剂量制剂被提出，其中硼替佐米具有显着改善的稳定性。 特别优选的制剂包括硼替佐米是适合注射的液体形式的制剂，其中溶剂体系主要包含丙二醇。 在其他优选方面，硼替佐米作为具有异双功能路易斯碱的路易斯供体 - 受体复合物存在。
-
公开(公告)号：US09107821B2
公开(公告)日：2015-08-18
申请号：US13592228
申请日：2012-08-22
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
摘要翻译： 硼替佐米的多剂量制剂被提出，其中硼替佐米具有显着改善的稳定性。 特别优选的制剂包括硼替佐米是适合注射的液体形式的制剂，其中溶剂体系主要包含丙二醇。 在其他优选方面，硼替佐米作为具有异双功能路易斯碱的路易斯供体 - 受体复合物存在。
-
公开(公告)号：US20120322763A1
公开(公告)日：2012-12-20
申请号：US13592235
申请日：2012-08-22
申请人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
发明人： Kumaresh Soppimath , Satish Pejaver , Kanaiyalal R. Patel , Lakkaraju Dasaradhi , Rama Sodum , Hari Desu , Navneet Puri
IPC分类号： A61K31/69
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/19 , A61K31/4965 , A61K31/69 , A61K47/10 , C07B63/04
摘要： Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.023 秒)
